BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease

Annals of the Rheumatic Diseases

Volumn 74, Issue 8, 2015, Pages 1596-1602

  Cangi, Maria Giulia ^a   Biavasco, Riccardo ^b   Cavalli, Giulio ^a,b   Grassini, Greta ^a   Dal Cin, Elena ^a   Campochiaro, Corrado ^a,b   Guglielmi, Barbara ^a   Berti, Alvise ^a,b   Lampasona, Vito ^a   Von Deimling, Andreas ^c   Sabbadini, Maria Grazia ^a,b   Ferrarini, Marina ^a   Doglioni, Claudio ^a,b   Dagna, Lorenzo ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; GENOMIC DNA; MITOGEN ACTIVATED PROTEIN KINASE; BRAF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; ENZYME ACTIVATION; ERDHEIM CHESTER DISEASE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HISTIOCYTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LOCKED NUCLEIC ACID POLYMERASE CHAIN REACTION; MALE; MIDDLE AGED; MOLECULAR BIOLOGY; MONOCYTE; NUCLEIC ACID ANALYSIS; ONCOGENE INDUCED SENESCENCE; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PYROSEQUENCING; SENESCENCE; CELL AGING; GENETICS; METABOLISM; MONONUCLEAR CELL; MUTATION; ONCOGENE; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PROCEDURES; SEQUENCE ANALYSIS;

ADULT; AGED; CELL AGING; ERDHEIM-CHESTER DISEASE; FEMALE; HISTIOCYTES; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; MUTATION; ONCOGENES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; SEQUENCE ANALYSIS;

EID: 84940385131     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-204924     Document Type: Article

References (43)

1. Haroche J, Arnaud L, Amoura Z. Erdheim-Chester disease. Curr Opin Rheumatol 2012;24:53-9.
2. Haroche J, Arnaud L, Cohen-Aubart F, et al. Erdheim-Chester disease. Rheum Dis Clin North Am 2013;39:299-311.
3. Cavalli G, Guglielmi B, Berti A, et al. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis 2013;72:1691-5.
4. Della Torre E, Dagna L, Mapelli P, et al. Erdheim-Chester disease: imaging-guided therapeutic approach. Clin Nucl Med 2011;36:704-6.
5. Arnaud L, Hervier B, Neel A, et al. CNS involvement and treatment with interferon-Alpha are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011;117:2778-82.
6. Chetritt J, Paradis V, Dargere D, et al. Chester-Erdheim disease: a neoplastic disorder. Hum Pathol 1999;30:1093-6.
7. Al-Quran S, Reith J, Bradley J, et al. Erdheim-Chester disease: case report, PCR-based analysis of clonality, and review of literature. Mod Pathol 2002;15:666-72.
8. Vencio EF, Jenkins RB, Schiller JL, et al. Clonal cytogenetic abnormalities in Erdheim-Chester disease. Am J Surg Pathol 2007;31:319-21.
9. Stoppacciaro A, Ferrarini M, Salmaggi C, et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006;54:4018-22.
10. Dagna L, Girlanda S, Langheim S, et al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology (Oxford) 2010;49:1203-6.
11. Arnaud L, Gorochov G, Charlotte F, et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011;117:2783-90.
12. Ferrero E, Belloni D, Corti A, et al. TNF-Alpha in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology 2013;53:198-200.
13. Aouba A, Georgin-Lavialle S, Pagnoux C, et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010;116:4070-6.
14. Dagna L, Corti A, Langheim S, et al. Tumor necrosis factor alpha as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol 2012;30:e286-290.
15. Haroche J, Charlotte F, Arnaud L, et al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012;120:2700-3.
16. Blombery P, Wong SQ, Lade S, et al. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol 2012;30:e331-332.
17. Emile JF, Charlotte F, Amoura Z, et al. BRAF Mutations in Erdheim-Chester Disease. J Clin Oncol 2013;31:398.
18. Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood 2010;116:1919-23.
19. Sahm F, Capper D, Preusser M, et al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood 2012;120: e28-34.
20. Yousem SA, Dacic S, Nikiforov YE, et al. Pulmonary Langerhans Cell Histiocytosis: Profiling of Multifocal Tumors Using Next-Generation Sequencing Identifies Concordant Occurrence of BRAF V600E Mutations. Chest 2013.
21. Satoh T, Smith A, Sarde A, et al. B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease. PloS one 2012;7:e33891.
22. Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013;121:1495-500.
23. Galabova-Kovacs G, Kolbus A, Matzen D, et al. ERK and beyond: insights from B-Raf and Raf-1 conditional knockouts. Cell Cycle 2006;5:1514-8.
24. Wellbrock C, Hurlstone A. BRAF as therapeutic target in melanoma. Biochem Pharmacol 2010;80:561-7.
25. Li Y, Nakamura M, Kakudo K. Targeting of the BRAF gene in papillary thyroid carcinoma (review). Oncology reports 2009;22:671-81.
26. Tiacci E, Trifonov V, Schiavoni G, et al. BRAF mutations in hairy-cell leukemia. N Engl J Med 2011;364:2305-15.
27. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-Associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4.
28. Kriegl L, Neumann J, Vieth M, et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod Pathol 2011;24:1015-22.
29. Jacob K, Quang-Khuong DA, Jones DT, et al. Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas. Clin Cancer Res 2011;17:4650-60.
30. Acosta JC, Banito A, Wuestefeld T, et al. A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nature cell biology 2013;15:978-90.
31. Arcila M, Lau C, Nafa K, et al. Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13:64-73.
32. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 2011;122:11-19.
33. Oldenburg RP, Liu MS, Kolodney MS. Selective amplification of rare mutations using locked nucleic acid oligonucleotides that competitively inhibit primer binding to wild-type DNA. J Invest Dermatol 2008;128:398-402.
34. Kuilman T, Michaloglou C, Vredeveld LC, et al. Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 2008;133:1019-31.
35. Braumuller H, Wieder T, Brenner E, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494:361-5.
36. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007;445:656-60.
37. Hoenicke L, Zender L. Immune surveillance of senescent cells-biological significance in cancer-And non-cancer pathologies. Carcinogenesis 2012;33:1123-6.
38. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012;367:107-14.
39. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367:1694-703.
40. Ho AL, Grewal RK, Leboeuf R, et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl J Med 2013;368:623-32.
41. Jang S, Atkins MB. Which drug, and when, for patients with BRAF-mutant melanoma Lancet Oncol 2013;14:e60-9.
42. Diamond EL, Abdel-Wahab O, Pentsova E, et al. Detection of an NRAS mutation in Erdheim-Chester disease. Blood 2013;122:1089-91.
43. Dorr JR, Yu Y, Milanovic M, et al. Synthetic lethal metabolic targeting of cellular senescence in cancer therapy. Nature 2013;501:421-5.